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Abstract
Major efforts have been invested in the identification of cancer biomarkers in plasma, but the extraordinary dynamic range
in protein composition, and the dilution of disease specific proteins make discovery in plasma challenging. Focus is shifting
towards using proximal fluids for biomarker discovery, but methods to verify the isolated sample’s origin are missing. We
therefore aimed to develop a technique to search for potential candidate proteins in the proximal proteome, i.e. in the
tumor interstitial fluid, since the biomarkers are likely to be excreted or derive from the tumor microenvironment. Since
tumor interstitial fluid is not readily accessible, we applied a centrifugation method developed in experimental animals and
asked whether interstitial fluid from human tissue could be isolated, using ovarian carcinoma as a model. Exposure of
extirpated tissue to 106 g enabled tumor fluid isolation. The fluid was verified as interstitial by an isolated fluid:plasma ratio
not significantly different from 1.0 for both creatinine and Na+, two substances predominantly present in interstitial fluid.
The isolated fluid had a colloid osmotic pressure 79% of that in plasma, suggesting that there was some sieving of proteins
at the capillary wall. Using a proteomic approach we detected 769 proteins in the isolated interstitial fluid, sixfold higher
than in patient plasma. We conclude that the isolated fluid represents undiluted interstitial fluid and thus a subproteome
with high concentration of locally secreted proteins that may be detected in plasma for diagnostic, therapeutic and
prognostic monitoring by targeted methods.
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Introduction
Significant efforts have been invested in the search for
biological disease indicators in plasma, for diagnostic and
prognostic purposes [1]. However, the high range of protein
concentrations in plasma is a major obstacle in biomarker
discovery using proteomics [2]. Many proteins suggested as
biomarkers are relatively abundant and related to non-specific
global reactions to the disease resulting in low sensitivity and
specificity, thus most candidates are never translated into
clinical use [3,4]. Furthermore, proteins secreted from tumor
cells and shed membrane proteins will have several orders of
magnitude higher concentration in the tumor extracellular or
interstitial microenvironment compared to plasma [5]. In the
search for tumor specific biomarkers the focus should accord-
ingly be on the tumor interstitial environment and the
secretome and thus in the fluid phase bathing the tumor cells
and the extracellular matrix elements, i.e. in the tumor
interstitial fluid (TIF) [6]. To our knowledge there is, however,
no technique available whereby native interstitial fluid can be
isolated from solid human tumors.
Microdialysis is a technique frequently used to access the
interstitial space in experimental animals and humans in vivo, but
because of low recovery of macromolecules, fluid isolated with this
technique will not reflect the protein composition of native
interstitial fluid [7,8,9]. Attempts have been made to isolate TIF ex
vivo and to apply this fluid as substrate for proteomic analysis
[6,10,11,12]. Little evidence has, however, been presented that
such fluid originates solely from the interstitial fluid phase.
Admixture of intracellular proteins in the isolated TIF will result
in identification of proteins that will not be secreted and may thus
be erroneously identified as biomarker candidates. By isolating
native or undisturbed TIF without causing cellular damage, the
sample will be a pre-sorted selection of proteins with character-
istics that are required for proteins to be used as biomarkers (i.e.
produced in the tumor), making detection of clinically relevant
biomarker candidates more likely.
As pointed out in a recent review [9], access to native fluid will
enable us to address a wide range of questions regarding the tumor
microenvironment and tumor biology in general. As an example,
we may measure interstitial fluid colloid osmotic pressure (COP),
one of the determinants of transcapillary fluid exchange that also
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give information on sieving properties of tumor capillaries.
Moreover, in native TIF we may also quantify the local production
of signaling and tissue specific substances, knowledge of impor-
tance to understand how tumors develop and progress.
In the present study we asked whether a method developed for
isolation of TIF in experimental animals [13] could be translated
for use in human solid tumors. As an example we used ovarian
carcinoma, representing the most lethal gynecological malignancy,
with the majority of cases diagnosed with metastatic disease [4]. In
order to verify the origin of the isolated fluid we quantified the
admixture of intracellular fluid by relating the concentration of
endogenous substances present predominantly in the extracellular
fluid phase in isolated fluid to that of plasma, and were able to
demonstrate that such admixture was negligible. We utilized the
isolated fluid to determine for the first time interstitial fluid colloid
osmotic pressure in a human solid malignant tumor, and could
furthermore show that such fluid is a relevant substrate in a
subproteome analysis when searching for tumor specific proteins.
The presented new technique may serve as a useful tool in studies
of the tumor cell microenvironment.
Results
The extirpated human ovarian tumor samples (weight range
0.3–5 grams) used in the present study were from the tumor
surface in an area without any apparent necrosis or inflammation,
and the tumor fluid was isolated immediately after extirpation by
centrifugation for 10 minutes. The tumor fluid yield after
centrifugation ranged from 5 to 150 ml/g tissue, and the isolated
fluid had a yellow, clear color. Fluid could be isolated from all
tumor samples at 106 g.
Validation by extracellular markers
In order to address whether the tumor fluid derived from the
extracellular space only or had admixture of intracellular fluid, we
designed an assay (Figure 1A) based on measuring the concentra-
tion of two endogenous substances, creatinine and Na+. These
substances are present predominantly in the extracellular fluid
phase and should therefore have similar concentrations in plasma
and interstitial fluid [14,15,16].
The tumor fluid:plasma ratios were 0.9860.09 for creatinine
(n = 7) and 1.0060.04 for Na+ (n = 7) (Figure 1B). Dilution with
intracellular fluid would result in a ratio lower than unity, and
neither the creatinine nor the Na+ values were significantly
different from 1.0 (One-sample t-test).
As an additional measure to study how cellular rupture and
release of intracellular proteins affected the creatinine and Na+
measurements we exposed frozen samples to 955 g, a procedure
known to cause such release [13], and these samples are referred to
as frozen tumor fluid. These samples gave a frozen tumor
fluid:plasma ratio that was significantly lower than 1.0 for both
substances (Mann-Whitney, p,0.05) averaging 0.6960.06 (n= 4)
for creatinine and 0.5960.09 (n= 6) for Na+ (Figure 1B),
suggesting that intracellular fluid with low concentrations of Na+
and creatinine had been added to the centrifugate.
The HPLC approach for determining creatinine concentration
and separation of creatinine from interfering chromogens is shown
in Figure 2A–C. To address possible interference in the creatinine
assay by chromogens [15] the enzymes creatininase and creatinase
were used to remove creatinine from the sample before analysis.
The signal after enzyme hydrolysis was minimal (Figure 2D)
suggesting that chromogens did not affect the creatinine
measurement.
Figure 1. Overview of the tumor fluid validation assay. A:
Illustration of the principle for validation of tumor fluid as interstitial
fluid. The concentrations of the extracellular markers, Na+ and
creatinine were compared in isolated tumor fluid and plasma. When
the isolated fluid derives solely from the interstitial space, the
concentrations of the markers are equal to that in plasma, while
addition of intracellular fluid will result in a lower tumor fluid:plasma
ratio. To assess the presence of intracellular proteins, mass spectro-
metric analysis was used, the resulting protein lists were filtered based
on known house keeping and extracellular proteins and the change in
the number of spectra for intracellular proteins relative to albumin was
used as an indicator of intracellular protein contamination. B: Measured
tumor fluid:plasma ratio for creatinine and Na+ for tumor fluid (black)
and frozen tumor fluid (grey). Values are mean 6 SEM. *: Significantly
different from tumor fluid (p,0.05) (Mann-Whitney test).
doi:10.1371/journal.pone.0019217.g001
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Validation based on intracellular proteins
In order to determine the admixture of intracellular proteins
that may result from the handling of the tissue samples and the
centrifugation procedure, freshly isolated and frozen tumor fluid
were compared by a mass spectrometry (MS) approach without
prior fractionation. To study proteins that are mainly intracellular,
i.e. housekeeping proteins, the protein lists were filtered. First,
proteins identified in plasma and proteins assigned to the gene
ontology (GO) category cellular component ‘‘Extracellular’’ were
excluded. Second, proteins present in a list of housekeeping genes
predicted by a Naive Bayes classifier were included [17]. Fifteen
proteins matched the filtering criteria, and they are given in Table
S1. The sum of spectra for these housekeeping proteins was
normalized by the number of albumin spectra identified in tumor
Figure 2. Measurement of creatinine by HPLC. A: The complete chromatogram from HPLC creatinine analysis. Deproteinized samples were
injected on two strong cation exchange columns in series at pH 4.68, where creatinine will be positively charged and retained. TCA and other
contaminants are not retained at this pH and were washed out in the first five minutes, while creatinine was passed into a third column for further
separation and fixation. By changing the buffer pH to 7.01 in the third column the creatinine molecule was rendered neutral, reducing retention and
thus producing a sharp and well-defined peak with absorbance at UV 234 nm. After a focusing step the buffer pH changes back and the columns
were regenerated. B: Calibration curve for creatinine with standard concentrations 0, 10, 40, 80, 100 and 200 mM. C: Chromatograms for creatinine
standards 0, 10, 40 and 80 mmol/L used for calibration. D: By analyzing tumor fluid and plasma samples before and after enzyme hydrolysis by
creatininase and creatinase the method’s specificity could be assessed. The chromatograms from analysis of plasma, tumor fluid before and after
enzyme hydrolysis, and a blank run are shown.
doi:10.1371/journal.pone.0019217.g002
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fluid and frozen tumor fluid, respectively. We found that the
number of spectra representing intracellular proteins increased by
80% in frozen tumor fluid compared to the tumor fluid, suggesting
a significant addition of intracellular proteins to the frozen tumor
fluid.
COP
Since the isolated tumor fluid obtained from the tumor was
undiluted, we were able to measure the COP in interstitial fluid of
human ovarian tumors (Figure 3). The COP averaged
24.063.0 mmHg in tumor fluid (n = 6), significantly different
from the corresponding pressure in plasma of 30.362.0 mmHg
(n = 6) (p,0.05, Wilcoxon matched-pairs signed rank test), thus
resulting in a tumor fluid:plasma COP ratio of 0.7960.08.
Characterization of proteins in tumor fluid compared to
plasma and ascites
To characterize the tumor fluid with respect to protein
composition, tumor fluid, plasma and ascites were analyzed by
size-exclusion chromatography before and after immunodepletion
of the 14 most abundant plasma proteins. Before immunodeple-
tion all samples were dominated by the presence of high
abundance plasma proteins with albumin as the most marked
peak with retention time of 30.5 minutes (Figure 4A), but tumor
fluid also presented with a higher signal compared with ascites and
plasma showing that there were more proteins eluting in the low
molecular weight area after albumin. The chromatograms were
normalized to albumin. After immunodepletion the overall protein
composition in the samples changed (Figure 4B). At a retention
time of 29 minutes, all three samples had a dominating peak, that
we have shown is concurrent with hemopexin (unpublished
observations), and all three chromatograms were normalized to
this peak. The ascites sample still had a marked peak at the
retention time for albumin at 30.5 minutes, but was otherwise
similar to plasma. In contrast, tumor fluid differed significantly
from plasma and ascites both in the first part of the chromato-
gram, at 15 to 20 minutes, and after 30 minutes. This analysis
showed that the TIF contained significant amounts of potential
tumor specific proteins that were not detectable in plasma or
ascites and may thus serve as an improved substrate for proteomic
analysis.
Proteomic analysis
The tumor fluid was investigated as a starting point for
biomarker discovery using a proteomic approach. The proteomic
analysis resulted in identification of 769 proteins in the tumor
fluid, 124 in patient plasma and 102 in control plasma (Figure 5).
Protein lists are given in Table S2. The two plasma proteomes had
Figure 3. Colloid osmotic pressure (COP) in plasma and tumor
fluid samples. COP was measured in paired plasma and tumor fluid
samples using a colloid osmometer with a 30 kDa cut off-membrane.
Corresponding pressure measurements in plasma and tumor fluid have
been connected.
doi:10.1371/journal.pone.0019217.g003
Figure 4. Chromatographic evaluation of tumor fluid, plasma
and ascites by size-exclusion chromatography. A: Size exclusion-
chromatography of native tumor fluid, plasma and ascites, results are
normalized in respect to albumin. As expected, albumin was a major
constituent, and all three samples were dominated by major plasma
proteins. The chromatogram for tumor fluid indicates that there were
some low molecular weight proteins present in tumor fluid that were
not found in ascites or plasma. B: After immunoaffinity depletion of the
14 most abundant plasma proteins, the ascites and plasma samples
were still similar, except from an albumin peak for ascites that can
indicate incomplete depletion of albumin. Tumor fluid reveals large
differences in the protein composition compared to plasma and ascites,
indicating the presence of tumor specific proteins in tumor fluid.
Results were normalized in respect to the peak at a retention time of 29
minutes.
doi:10.1371/journal.pone.0019217.g004
Isolating Undiluted TIF from Human Ovarian Tumors
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19217
66% of the proteins identified in common, an overlap that is
expected with two technical replicates of the same sample [18,19],
whereas more than six times as many proteins were identified in
tumor fluid compared to plasma, underlining the difficulty to find
disease-specific changes in the plasma proteome. Among the
proteins found in both patient plasma and tumor fluid we
identified the established biomarker CA-125 (Q8WXI7), and
among the 708 proteins detected only in tumor fluid the new
biomarker candidate Osteopontin (P10451) [20,21] was also
found, as well as a large number of proteins that have yet to be
explored as biomarker candidates.
The protein composition according to GO cellular component
may indicate the origin of the proteins found in tumor fluid and
patient plasma. For patient plasma 90.3% and 51.6% of the
proteins identified were annotated with the GO category
‘‘Extracellular’’ and ‘‘Cytoplasm’’ respectively, whereas tumor
fluid had 27.8% of the proteins annotated as ‘‘Extracellular’’ and
83.4% as ‘‘Cytoplasm’’.
In an attempt to investigate whether our method of interstitial
fluid isolation has the potential to reveal new biomarker candidates
that is not identified with alternative methods, we compared the
769 proteins found in TIF with data from previous in-depth
proteomic analysis of ovarian cancer cell line cultures [22] and
ascites deriving from ovarian cancer patients [23]. Interestingly,
we were able to detect 454 proteins in TIF that were not found in
the other proteomes (Figure 6), suggesting that access to the tumor
subproteome through TIF represents an important new source for
biomarker candidate proteins.
Discussion
Here we have presented a method to isolate native interstitial
fluid from a solid human tumor and verified that the isolated fluid
derives from the extracellular fluid phase. Even though the
interstitial fluid is an important element of the tissue microenvi-
ronment, TIF has been coined as a ‘‘misconsidered component of
the internal milieu of a solid tumor’’ [24]. The reason is most likely
a paucity of methods for TIF isolation [9], and we have thus
provided a new tool to remedy this situation.
The critical question in our work is whether fluid isolated by
centrifugation is representative for the interstitial fluid. Previously
we have addressed this issue in animal studies by using the
extracellular tracer 51Cr-EDTA [13], whereas an alternative
approach is necessary for studies of human tissue. We therefore
used two endogenous substances, creatinine and Na+ to assess if
the tumor fluid is representative for TIF.
Creatinine originates from degradation of creatine, which
mainly occurs in skeletal muscle tissue harboring 98% of the
bodily creatine [15], diffuses out from the cells and into plasma,
and is present in equilibrium in the extracellular fluids of the body
[15].
Na+ is in equilibrium between plasma and the interstitial fluid
[14,16], and has a relatively high concentration in the extracellular
(145 mM) as compared with the intracellular fluid phase (4 mM).
Both substances are, however, restricted from entering the cell.
Our finding that the ratios for the concentrations of Na+ and
creatinine in tumor fluid compared to plasma were not
significantly different from 1.0, suggests that the isolated fluid is
not diluted by intracellular fluid.
Obviously, the isolated fluid derives from the entire extracellular
fluid phase, and will therefore include some plasma. Using 125I-
labeled serum albumin, we have assessed this fraction in fluid
isolated by centrifugation from chemically induced mammary
carcinomas in rats [13], another solid epithelial tumor. At a G-
force similar to what was applied in the present study, we found
Figure 5. Overview of proteomic results for tumor fluid
compared to plasma. Pooled plasma and tumor fluid samples of
three patients with ovarian cancer and a control pool taken from five
women operated for suspected ovarian carcinomas later shown to be
benign were immunoaffinity depleted, fractionated by reversed phase
and strong cation exchange chromatography at protein level and nano-
reversed phase liquid chromatography at peptide level before analysis
by tandem mass spectrometry. Venn-diagram of the three proteomes
identified from tumor fluid (left), patient plasma (lower right) and
control plasma (upper right). Analyzing patient plasma compared to
control plasma yielded few new proteins, while the tumor fluid contains
a large amount of proteins not detected in plasma.
doi:10.1371/journal.pone.0019217.g005
Figure 6. Comparison of tumor fluid proteome with published
protein data. The proteins found in tumor fluid in the present study
(right) compared to proteomes presented for ascites by Gortzak-Uzan
et al. [23] (lower left) and ovarian cancer cell line cultures of Faca et al.
[22] (upper left). In ascites there were 268 proteins in addition to the
proteins found by proteomic analysis of ovarian cancer cell lines
cultures, while in the tumor fluid proteome, although with a much
lower total number of proteins identified, there were 454 proteins that
were neither detected in ascites nor in cell line cultures.
doi:10.1371/journal.pone.0019217.g006
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that,5% of the isolated fluid derived from plasma. Similar studies
are for obvious reasons not feasible in humans, but if we assume
that these tumors have comparable physicochemical properties we
may conclude that the fraction deriving from plasma is negligible
and thus that the isolated fluid represents TIF.
Having concluded that the tumor fluid is representative for TIF,
the finding of intracellular proteins in the same fluid shows that
there are some intracellular proteins in TIF. Furthermore, our GO
analysis indicates a larger fraction of extracellular proteins in
plasma than in tumor fluid. Still, as the tumor fluid originates in
the tissue, and plasma is a global extracellular fluid, a higher
fraction of cytoplasmic proteins in tumor fluid than in plasma is to
be expected. These proteins may derive from cellular catabolism in
vivo, which will affect the detection of intracellular proteins, but not
affect the creatinine- and Na+-ratios. This is consistent with the
finding of a large number of peptides derived from intracellular
sources in prenodal lymph [25,26], which is representative for
tissue interstitial fluid [9]. Intracellular proteins will also leak to
plasma, as evidenced by a significant amount of such proteins in
human serum [27]. It is also likely that the TIF contains peptides
deriving from extracellular matrix elements cleaved by matrix
metalloproteases known to be active in the tumor interstitium
[28,29]. Proteins deriving from necrotic areas may potentially
contaminate the sampled interstitial fluid. Although we cannot
exclude such contamination completely, there are several reasons
why we think this effect is small. When we isolated tumor tissue for
centrifugation, necrotic areas were avoided. Furthermore, fluid
isolated from necrotic areas of the tumor will likely lead to leakage
of intracellular fluid with low Na+ and creatinine to the
microenvironment, and thus result in reduced tumor fluid:plasma
ratios for these two extracellular markers. Assessing the distribu-
tion of proteins in cellular components as defined by GO may
indicate that there is a large amount of intracellular proteins
present. However, preliminary results from proteomic analysis of
interstitial fluid isolated from healthy ovarian tissue (unpublished)
gave a GO distribution highly similar to that found in TIF, again
supporting our assumption that the observed protein pattern is not
a result of tumor necrosis.
Intracellular contamination has to be considered when
interpreting proteomic data originating from frozen samples, e.g.
from biobanks, which may be used for targeted proteomics. If,
however, frozen tissue is used in a screening phase, this will result
in the detection of intracellular non-secretome candidate proteins.
Other methods like nipple aspirates and ductal lavage fluid have
been proposed for sampling of tumor subproteomes (for review see
[30]), and in-depth proteomic analyses have been performed on
peritoneal fluid [31] and ascites [23,32] for ovarian cancer. Ascites
fluid may accumulate in the peritoneal cavity of ovarian cancer
patients in advanced stages [3]. Such accumulation is a result of
malignant cells secreting proteins that cause neovascularization,
increased fluid filtration and lymphatic obstruction leading to build-
up of serum-like fluid within the abdomen [32]. That this fluid is
similar to plasma was also shown by our experiments, but we could
furthermore demonstrate that ascites deviates strongly from TIF
with respect to protein composition as illustrated by size-exclusion
chromatography. Thus, tumor specific proteins are likely up-
concentrated in tumor fluid compared to both plasma and ascites.
Moreover, since ascites accumulates at an advanced stage, such fluid
may, as suggested by Gortzak-Uzan and coworkers [23], not be so
useful to detect early disease protein expression signatures but rather
to predict outcome and treatment response. TIF sampling as
presented here will, however, give a protein signature that in
addition to being representative for an earlier stage of the disease
also enable us to quantify microenvironmental proteins.
Another method used for sampling of interstitial fluid from
human tumors is tissue elution [10]. By this method, fresh biopsies
obtained from women with invasive breast cancer are cut into small
pieces (1–3 mm3) and eluted in PBS. The supernatant is collected
after 1 hour and named TIF [10]. Sectioning of cell-rich tumors
into small pieces may result in admixture of intracellular fluid. The
major problem with this tissue elution method is thus to determine if
the identified peptides and proteins are representative for the
interstitial fluid or have entered the eluate from the intracellular
compartment during the PBS-equilibration period. Sun et al. [11]
addressed intracellular protein contamination in eluted TIF by
Western blot. Based on the fact that they were unable to find four
organelle specific proteins, they concluded that intracellular proteins
did not contaminate the TIF. Evidently, other intracellular proteins
may enter the extracellular phase during equilibration, since there is
a significant fraction of intracellular proteins even in normal serum
[27], suggesting that the finding of such proteins per se cannot be
used as evidence of intracellular fluid contamination.
Access to native, undiluted TIF has additional advantages.
Eluate will not as centrifugate reflect absolute concentration in
TIF of proteins and signaling substances, of importance for e.g.
protein expression and transcapillary fluid balance studies. The
determination of COP will only be feasible in undiluted samples,
and to our knowledge we are the first to report COP in human
tumor tissue, underlining the advantage of tumor fluid isolated by
centrifugation. The measured tumor fluid:plasma COP ratio of
0.79 is higher than in human skin [33], but consistent with earlier
findings for mammary tumors in rats [13]. A ratio ,1.0 indicates
that there is some sieving of proteins at the capillary wall of
tumors. Furthermore, this observation suggests that uptake of
therapeutic agents in tumors can be improved by using solutions
with high COP to lower interstitial fluid pressure as suggested by
experiments in mice [13,34].
As part of the validation of the method we performed a
proteomic analysis of the tumor fluid and found a sixfold increase
in the number of detected proteins compared to plasma, pointing
to TIF as a rich source for tumor specific proteins with biomarker
potential. Moreover, a comparison with published in-depth
proteomes for ovarian cancer derived from cell cultures and
ascites [22,23] showed that analysis of TIF and thus the native
tumor microenvironment resulted in the identification of a
significant number of additional proteins not found in these
earlier studies, emphasizing the value of our sampling approach.
One may argue that we present proteomics data on pooled fluid
from few patients and thus question the general validity of the
results. Our aim was to present an approach to isolate native TIF,
but our data may also be considered as an initial phase of
discovery proteomics. In this phase the main goal is to accumulate
a library of proteins that may serve as candidates for validation
strategies later [35]. Since the fractionation process is extensive
and requires large sample volumes, individual tumor fluid samples
were pooled to serve as a source for such an ovarian cancer library
based on tumor fluid and plasma. The method of pooling samples
has been presented as an approach to reduce the effects of
biological variation and with the additional benefit of a great
reduction in the total number of samples that has to be analyzed
[36,37]. Moreover, pooling of samples reduces the influence of
individual changes in protein composition and favors those
proteins present in all the individual samples that may serve as
more robust biomarker candidates. Further mining and validation
studies will clearly be needed to establish the potential roles for the
identified proteins as novel biomarker candidates.
To summarize, we have presented a centrifugation technique
that can be used to isolate undiluted fluid that qualitatively and
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quantitatively reflects human ovarian carcinoma interstitial fluid.
The method can be adapted for application in other solid tumors
and be used to address a wide range of questions regarding the
tumor microenvironment and tumor biology. Additionally, as
suggested here, it can be used for identification of candidate
proteins for diagnostic and prognostic use as well as targets for
molecular imaging and therapy.
Materials and Methods
The research protocol has been approved by the Norwegian
Data Inspectorate (Protocol # 961478-2), Norwegian Social
Sciences Data Services (Protocol # 15501) and the local ethical
committee (Protocol ID REKIII nr. 052.01). All samples were
collected after obtaining the patients’ written informed consent.
The work conformed to the standards set by the latest revision of
the Declaration of Helsinki.
Sample collection
Samples from extirpated human ovarian tumors were collected
from the Department of Obstetrics and Gynecology at Haukeland
University Hospital. The samples were taken from the tumor
surface in an area without any apparent necrosis or inflammation,
and ascites fluid was collected in patients presenting with fluid in
the abdominal cavity. Blood samples were collected from the
patients 1–2 days before surgery and EDTA was used as the
coagulation agent. Tumor fluid was isolated immediately after
extirpation by centrifugation as described earlier [13] at 106 g for
10 minutes, and fluid without erythrocytes were collected and
stored280uC until further processing. Fluid that was isolated from
fresh tissue is referred to as tumor fluid. As a positive control for
admixture of intracellular fluid, a piece of the tumor sample was
frozen without centrifugation, and subsequently thawed and
centrifuged at 955 g for 10 minutes, referred to as frozen tumor
fluid. Ascites fluid was centrifuged to remove the cellular fraction,
and cell free ascites fluid was extracted. The fluid samples were
stored at 280uC until further processing. The sample validation
strategy is outlined in Figure 1A.
Creatinine analysis
The concentration of creatinine was measured in individual
samples (n = 7) by HPLC on an Agilent HPLC system, using the
principle presented by Ambrose et al. [38]. Ten ml samples were
deproteinated by 90 ml 5% TCA and spun at 20 000 g for 10
minutes to remove precipitated proteins, 98 ml of supernatant was
pipetted off, and 50 ml supernatant was injected in the HPLC
system with 20 mM sodium acetate buffer (pH 4.68). At this pH
creatinine, with a pKa of 5.02, is positively charged and has some
retention on two strong cation exchange (SCX) columns. A Bio-
Monolith SO3 column (5.264.95 mm, Part no.: 5069-3637,
Agilent Technologies, Santa Clara, CA) in series with a Resource
S column (1 ml, Code no. 17-1178-01, GE Healthcare, United
Kingdom) were used for separation of creatinine from TCA and
other contaminants. Further separation was done with a Proswift
SCX-1S Analytical column (4,6650 mm, 066765, Dionex,
Sunnyvale, CA) and by changing the buffer to 10 mM phosphate
buffer (pH 7.01) in the third column the creatinine molecule is
rendered neutral, reducing the retention in the column and
focusing it, thus producing a sharp and well-defined peak with
absorbance at UV 234 nm.
The specificity of the method was tested by analyzing plasma
and tumor fluid before and after enzyme hydrolysis by creatinase
(EC 3.5.3.3, 500 U, Sigma-Aldrich, St. Louis, MO) and
creatininase (EC 3.5.2.10, 1000 U, Sigma-Aldrich) as suggested
by Paroni et al. [39]. The lyophilized enzymes were reconstituted
in 100 mM phosphate buffer (50 mM Na2HPO4 + 50 mM
NaH2PO4) to a final concentration of 50 and 90 U/ml for
creatininase and creatinase, respectively. Ten ml of sample was
incubated at 25uC overnight with 5 ml of each enzyme added. The
following day the sample was deproteinated by adding 80 ml of 5%
TCA and processed further as described above.
Sodium analysis
The concentration of Na+ was measured in individual samples
(n = 7) by an AAnalyst 200 flame spectrometer (PerkinElmer,
Waltham, MA). The instrument was calibrated using solutions
with Na+-concentrations of 10, 20, 50, 100 and 200 mM that were
further diluted 1:1000 in 0.65% HNO3. Five ml of sample was
diluted in 10 ml 0.65% HNO3 and the concentration was
measured in triplicate. All sample measurements were in the
linear area of the calibration curve, between 10 and 100 mM.
COP
COP was determined in tumor fluid and plasma for individual
samples (n = 6) in a colloid osmometer using a membrane with
cutoff 30 kDa and equipped with a transducer as described in
detail in an earlier publication [40].
Sample fractionation and proteomic analysis
For proteomic analysis equal volumes of tumor fluid from three
tumor samples and the respective plasma samples were pooled and
an overview of the patient samples used is given in Table 1. None
of the patients received neoadjuvant therapy, and all had a
preoperational CA-125 concentration of more than 10 times
higher than the cut-off concentration of 35 U/mL. Pooled plasma
from five women operated for suspected cancerous growths later
shown to be benign served as control. The pooled samples were
depleted of the 14 most abundant plasma proteins using a Hu-14
Multiple Affinity Removal Column (4,6650 mm, 5188-6557,
Agilent Technologies), in accordance with the manufacturer’s
recommendations.
The flow-through fraction from the immunodepletion was
denatured by adding 0.48 g/ml urea and 13 ml/ml neat acetic
acid and the samples were injected onto a macroporous Reversed-
Phase (mRP) C18 Column (4.6650 mm, 5188-5231, Agilent
Technologies) and fractionated, following recommendations by
the manufacturer.
Fraction collection was started at retention time 4 minutes.
Twenty-three mRP-fractions of 1.8 ml were collected, evaporated
(Eppendorf Concentrator 5301) and subsequently diluted in
100 mM ammonium bicarbonate, denatured and digested by
trypsin in accordance with a protocol provided by Agilent
Technologies (www.chem.agilent.com; publication no. USH-
UPO3), desalted by C-18 spin columns (Pepclean C-18, 89870,
Pierce, Rockford, IL) and analyzed by liquid chromatography
coupled with tandem MS (LC-MS/MS) with an Agilent 1100 LC/
MSD Trap XCT Plus system with a HPLC-Chip/MS interface.
The HPLC-Chip contained a 0.075643 mm ZORBAX 300SB
C18 5- mm column and an integrated 9 mm 160 nL enrichment
column packed with the same material (part no. G4240-63001
SPQ110, Agilent Technologies). In addition, tumor fluid and frozen
tumor fluid from two patients were digested by trypsin and analyzed
by LC-MS/MS in triplicate without any prior separation. The
enzyme-to-protein ratio used in the digestion protocol was 1:35. For
two-dimensional LC-MS/MS, each mRP fraction was separated
further offline on a SCX column (ZORBAX BioSCX Series II,
0.8 mm650 mm, 3.5 mm; strong cation exchanger, 5065-9942,
Agilent Technologies) before MS analysis. Spectrum Mill MS
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proteomics workbench software (Rev A.03.02.060, Agilent Tech-
nologies) was used to process the MS spectra and identifications
were accepted with at least two unique peptides and with a score of
more than 13. Proteincenter (Software Version 3.0.4, Proxeon
Bioinformatics A/S, Odense, Denmark) was used for processing the
MS results, and Graphpad Prism was used for statistical analysis
(Software version 5.0, Graphpad Software Inc, La Jolla, CA).
Results are presented as mean 6 SEM.
Size-exclusion chromatography
Pooled samples of control plasma (n= 5), ascites (n= 9) and
tumor fluid (n= 6) were analyzed by size exclusion chromatography
before and after immunoaffinity depletion on a TSKgel SW2000
(4.66300 mm, 18674, Tosoh Bioscience, Tokyo, Japan) and a
TSKgel SW3000 (4.66300 mm, 18675, Tosoh Bioscience) coupled
in series. Samples that were not immunodepleted were diluted 1:100
in mobile phase buffer (0.1 M Na2SO4 in 0.1 M phosphate buffer,
pH 6.8). Immundepleted samples were not diluted, and 20 mL of all
samples were injected on the HPLC system for separation.
Supporting Information
Table S1 Intracellular proteins. Number of spectra identi-
fied for albumin and 15 selected intracellular proteins.
(PDF)
Table S2 Information on identified proteins. Summary of
identified proteins, with detailed information, in tumor fluid,
patient plasma and control plasma with a Spectrum Mill score
higher than 13 and at least two peptides.
(XLS)
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